Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Revenue projections:

Revenue projections for GILD
Revenue projections for GILD

Gilead Sciences, Inc.'s revenue is projected to decrease from last year, a development that could lead investors to adopt a more cautious approach. A revenue decline can negatively affect profitability, signaling challenges for the company and making it less attractive for those seeking solid financial performance.

Financial Ratios:

currentRatio 1.553000
forwardPE 13.814422
debtToEquity 112.923000
earningsGrowth 0.234000
revenueGrowth 0.047000
grossMargins 0.788400
operatingMargins 0.373750
trailingEps 6.780000
forwardEps 9.620380

A current ratio of 1.553 for GILD implies that the company has ample liquidity to meet its short-term debts. GILD's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
GILD's Forward PE ratio suggests that the stock is priced appropriately in relation to its earnings. Not being overpriced, it offers room for growth, signaling potential upside for investors looking for a stock with reasonable valuation and growth potential.
GILD's high debt-to-equity ratio shows the company is significantly leveraged, relying heavily on debt financing. This raises the potential for increased financial risk, especially if the company's earnings or cash flow are negatively impacted.
GILD's positive gross and operating margins indicate the company's ability to operate profitably. These margins reflect strong financial management, with efficient cost control contributing to sustained profitability and a solid financial outlook.
GILD's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that GILD's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.

Price projections:

Price projections for GILD
Price projections for GILD

Price projections for GILD have been revised upward over time, signaling increasing optimism about the company's future. This steady increase reflects a positive outlook for GILD's growth and market performance.

Insider Transactions:

Insider Transactions for GILD
Insider Transactions for GILD


There were 34 transactions selling GILD stock, with prevailing market price of 121.16761353436638.During the period under consideration, there were no sell transactions.GILD's current price levels are experiencing more buying activity than selling, which may point to a favorable outlook. This trend suggests investor confidence in the stock's future, potentially indicating expectations of continued growth.

Recommendation changes over time:

Recommendations trend for GILD
Recommendations trend for GILD


Analysts have shown a buy bias for Gilead Sciences, Inc., signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to Gilead Sciences, Inc., seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.